Clinically Significant Macular Edema Clinical Trial
The purpose of this is study is to assess the efficacy of navigated laser treatment in
reducing the number of anti-VEGF injections required to maintain visual gain obtained after
Bevacizumab compared to Bevacizumab alone in patients with clinically significant macular
edema (CSME).
This will be prospective, active-controlled study using Bevacizumab (Genentech, South San
Francisco CA) for intravitreal injections. Retinal photocoagulation will utilize the Navilas
Laser System (OD-OS GmbH, Teltow, Germany), which is an approved indication for this device.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03453281 -
Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection
|
Phase 4 | |
| Completed |
NCT02764697 -
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
|
Phase 4 | |
| Completed |
NCT01824862 -
Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema
|
N/A | |
| Completed |
NCT01698749 -
Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema
|
N/A |